Vaxcyte shares surge as Lancet publishes pivotal vaccine data
Phase 3 advancement for 31-valent pneumococcal candidate positions biotech against Pfizer, Merck
Vaxcyte shares rose sharply on Wednesday after the company announced that peer-reviewed data from its Phase 1/2 trial of VAX-31, a next-generation pneumococcal vaccine, was published in The Lancet Infectious Diseases. The publication marks a critical de-risking event for the $8.1 billion biotechnology company as it advances the vaccine candidate into late-stage development.
The study of 1,015 adults aged 50 and older demonstrated that the high-dose formulation of VAX-31 met non-inferiority criteria against Pfizer's market-leading Prevnar 20 across all 20 shared serotypes, while achieving statistical superiority for the 11 serotypes unique to Vaxcyte's candidate. The vaccine elicited robust immune responses across all 31 serotypes, with a safety profile comparable to existing standard-of-care options over a six-month evaluation period.
"These unprecedented results published in a top-tier medical journal provide strong validation for our platform technology," the company stated in its announcement. "Based on these data, we have advanced VAX-31 High Dose into a comprehensive Phase 3 adult program."
The clinical significance of VAX-31 lies in its breadth of coverage. The 31-valent vaccine targets approximately 95% of invasive pneumococcal disease (IPD) and 88% of pneumococcal pneumonia in U.S. adults aged 50 and older, representing an incremental 14-34% broader IPD coverage than currently approved vaccines. This expanded protection could position Vaxcyte to capture significant market share in the global pneumococcal conjugate vaccine market, which is dominated by Pfizer's Prevnar franchise and Merck's newer Capvaxive (PCV21).
The regulatory path forward has been smoothed by the FDA's Breakthrough Therapy designation, which the agency expanded in May 2025 to include pneumonia prevention in adults in addition to invasive disease. The designation is intended to expedite development and review of drugs for serious or life-threatening conditions where preliminary clinical evidence indicates substantial improvement over existing therapies.
Vaxcyte's Phase 3 program, branded as the OPUS trials, will include head-to-head comparisons against both Prevnar 20 and Merck's Capvaxive. The company anticipates reporting topline data from the OPUS-1 pivotal non-inferiority trial in the fourth quarter of 2026, a timeline that analysts view as critical for maintaining momentum in the stock.
Analysts remain broadly bullish on the Foster City, California-based biotechnology company. The consensus price target of $109 implies more than 100% upside from current levels, with 10 of 11 analysts rating the shares as buy or strong buy and just one recommending hold. The strong analyst support reflects confidence in VAX-31's potential to disrupt a market that generated billions in revenue for Pfizer in 2025.
The competitive landscape has intensified with Merck's launch of Capvaxive, which offers broader coverage than Prevnar 20 but fewer serotypes than Vaxcyte's candidate. If VAX-31 demonstrates success in Phase 3 trials, it could emerge as the most comprehensive pneumococcal vaccine available, potentially commanding premium pricing and capturing significant market share from both established players.
Vaxcyte's $8.1 billion market capitalization reflects high expectations for the VAX-31 program, and the progression from Phase 1/2 to Phase 3 represents a meaningful reduction in clinical development risk. Institutional investors hold more than 104% of outstanding shares, indicating strong conviction among professional money managers despite the stock's volatility—the shares have traded in a 52-week range of $27.66 to $76.61.
The company reported no commercial revenue in its most recent fiscal year, typical for pre-commercial biotechnology companies, with negative earnings per share of $5.63. However, the potential market opportunity for a next-generation pneumococcal vaccine could transform Vaxcyte into a commercial-stage company with substantial revenue if Phase 3 trials succeed and regulatory approval follows.